Copper is required for the activity of several enzymes involved in energy production, antioxidant defense, connective-tissue formation and cellular signaling. The liver plays a central role in controlling the body’s copper balance, absorbing the metal from the diet, incorporating it into proteins and directing excess copper toward biliary excretion. This system depends on a network of transporters and binding proteins. Copper transporter 1, or CTR1, helps cells import copper, while ATP7A and ATP7B distribute it to intracellular destinations or remove it when levels rise. Ceruloplasmin carries much of the copper in the bloodstream, and additional chaperone proteins deliver the metal to specific enzymes. In healthy tissue, this carefully regulated traffic prevents copper from accumulating in its reactive, chemically dangerous form.

Cancer can disrupt that balance. Tumor cells often remodel nutrient uptake and energy production to sustain rapid proliferation, and copper appears to be part of this metabolic adaptation. The review highlights evidence that hepatocellular carcinoma may exploit the copper–MYC–CTR1 axis. MYC, a transcription factor frequently activated in cancer, can increase the expression of genes that support proliferation and metabolism, including pathways that influence copper uptake. Elevated CTR1 may consequently provide malignant cells with more copper, potentially supporting enzymes involved in mitochondrial respiration, antioxidant protection and signaling. At the same time, excessive or improperly localized copper can generate reactive oxygen species, damage proteins and membranes, and place severe pressure on the endoplasmic reticulum and mitochondria.

The most intriguing development is cuproptosis, a copper-dependent form of regulated cell death first described in 2022. Unlike apoptosis, which involves caspase activation and controlled cellular dismantling, cuproptosis is closely tied to mitochondrial metabolism and protein lipoylation. Lipoylation is a biochemical modification in which a lipoate group is attached to specific lysine residues on enzymes of the tricarboxylic acid cycle. These modified proteins are essential for processing nutrients and producing energy inside mitochondria. When copper enters susceptible cells in excessive amounts, it can bind directly or indirectly to lipoylated mitochondrial proteins, promoting their aggregation. At the same time, copper can destabilize iron–sulfur proteins, leading to proteotoxic stress and ultimately cell death.

This mechanism creates a possible distinction between tumor cells and normal cells. Many cancers depend heavily on mitochondrial respiration or retain active tricarboxylic acid-cycle pathways, making them potentially sensitive to copper-induced mitochondrial damage. The review discusses research showing that ARID1A-deficient hepatocellular carcinoma may be especially vulnerable when the TCA cycle is targeted through cuproptosis. ARID1A is a component of the chromatin-remodeling machinery, and its loss can alter gene expression, metabolism and stress responses. In experimental models, this genetic defect was associated with a metabolic weakness that could be exploited to produce synthetic lethality, a situation in which blocking one pathway is particularly destructive only when a second vulnerability is already present.

Copper’s effects in liver cancer are not limited to direct toxicity. The metal can influence angiogenesis, the process through which tumors build new blood vessels. Research cited in the review connects copper transport and copper-dependent signaling with vascular endothelial growth factor pathways, including VEGFR2 signaling. Because growing tumors require oxygen and nutrients, changes in copper availability may affect not only cancer-cell metabolism but also the surrounding blood-vessel network. Copper can also interact with inflammatory signaling, antioxidant systems and the tumor microenvironment. These effects may influence immune-cell behavior, stromal remodeling and the capacity of malignant cells to invade nearby tissue.

The therapeutic possibilities are therefore moving in two opposite directions. One strategy is to increase copper stress inside cancer cells. Copper ionophores such as elesclomol can transport copper across membranes and direct it toward mitochondria, while disulfiram, an established drug used to treat alcohol dependence, can form copper-containing complexes with potential anticancer activity. By increasing intracellular copper or changing its distribution, these agents may push metabolically vulnerable tumor cells toward cuproptosis. Nanoparticles and drug-delivery systems are also being investigated as ways to concentrate copper or copper-based compounds within tumors. Such approaches could theoretically improve selectivity, but their safety depends on controlling exposure in the liver, an organ that naturally handles copper and is already vulnerable in patients with cirrhosis or chronic hepatitis.

The opposite strategy is copper deprivation. Chelating agents can bind copper and reduce its availability to cancer cells, potentially suppressing copper-dependent growth, angiogenesis or epithelial–mesenchymal transition, a process associated with invasion and metastasis. This approach could also influence resistance to chemotherapy and radiotherapy. However, copper depletion is not automatically beneficial: normal tissues require copper for essential enzymes, immune function and blood formation. The challenge is to distinguish the copper requirements of a tumor from those of healthy organs. The review therefore presents copper metabolism as a precision-treatment target rather than a simple “more is harmful” or “less is better” system.

The connection between cuproptosis and other forms of regulated cell death may make combination therapy especially powerful. Copper-dependent mitochondrial injury can overlap with oxidative stress, ferroptosis and autophagy. Ferroptosis is driven by iron-dependent lipid peroxidation, whereas cuproptosis centers on copper, lipoylated mitochondrial proteins and proteotoxic stress, but the pathways can interact through glutathione, reactive oxygen species and nutrient metabolism. Studies cited by the authors suggest that disulfiram and copper may consume glutathione and cooperate with suppression of the xCT antioxidant pathway, creating a cascade involving both ferroptosis and cuproptosis. Other experimental work has explored combinations with chemotherapy, radiotherapy, immune-based treatment and engineered nanomaterials. These findings raise the possibility that copper manipulation could sensitize resistant tumors rather than act as a stand-alone therapy.

Yet the field remains far from routine clinical use. Much of the current evidence comes from cell cultures, animal models or retrospective analyses of gene-expression datasets. Cuproptosis-related signatures have been associated with prognosis, immune activity and treatment sensitivity in hepatocellular carcinoma, but a gene-expression pattern is not the same as proof that cuproptosis is occurring in an individual patient. Researchers still need reliable biomarkers showing copper distribution, mitochondrial lipoylation, protein aggregation and pathway activation in living tumors. They must also determine how hypoxia, a common feature of solid cancers, affects treatment response. Recent research indicates that HIF-1α can promote resistance to cuproptosis, suggesting that oxygen availability and metabolic adaptation may decide whether copper-based therapy succeeds. The review concludes that carefully designed clinical studies, improved delivery systems and patient selection will be essential. If those challenges can be solved, copper homeostasis may become more than a biochemical curiosity: it could provide a new route for attacking liver cancer through the very metabolism that allows it to grow.

Subject of Research: Copper homeostasis, cuproptosis, mitochondrial metabolism and therapeutic strategies in hepatocellular carcinoma

Article Title: Cuproptosis in hepatocellular carcinoma: bridging copper homeostasis with therapeutic horizons

Article References: Tsvetkov P, Coy S, Petrova B et al. “Copper induces cell death by targeting lipoylated TCA cycle proteins.” Science 375, 1254–1261 (2022). DOI: 10.1126/science.abf0529; Xing T, Li L, Chen Y et al. “Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma.” Cell Reports Medicine 4, 101264 (2023). DOI: 10.1016/j.xcrm.2023.101264; Fan S, Wang A, Peng R et al. “Cuproptosis in hepatocellular carcinoma: bridging copper homeostasis with therapeutic horizons.” Molecular Biology Reports 53, 1412 (2026).

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12605-0

Keywords: Hepatocellular carcinoma, copper homeostasis, cuproptosis, copper metabolism, mitochondrial metabolism, oxidative stress, ferroptosis, cancer therapy, tumor microenvironment, precision oncology

Researchers designed a biocompatible nanoparticle platform based on PLGA-PEG, widely used in drug delivery because it is stable in circulation and breaks down in biological environments. To help the particles preferentially associate with tumor tissue, the team grafted iRGD, a tumor-penetrating peptide known for enhancing cellular uptake in cancer cells.

The therapeutic payload is TPEN, a chelator that binds metal ions, including copper. In this design, TPEN is delivered directly into cancer cells, where it can coordinate endogenous copper species and push the cells toward copper-dependent death without relying on externally administered metal. This reframes cuproptosis as an exploit of the tumor’s own biochemical resources.

The optimized formulation, TPEN@1%-iPPN, was engineered to be uniform, with nanoparticles averaging roughly 80 nm—an architecture favorable for tumor accumulation. In stability tests that mimic key features of blood circulation, the particles remained intact after dilution and exposure to serum proteins, supporting delivery of the chelator to the intended cellular compartment.

Release kinetics were also assessed: TPEN was found to be released in a sustained manner over about 72 hours. Such prolonged cargo liberation can help maintain therapeutic pressure within the tumor microenvironment rather than producing a short-lived drug pulse.

Targeting performance was evaluated in 4T1 breast cancer cells using complementary imaging and quantitative cytometry. Compared with non-targeted nanoparticles, iRGD-modified particles showed markedly greater cellular uptake, consistent with improved binding and internalization.

Importantly, functional assays supported selectivity. The targeted TPEN@1%-iPPN exhibited substantially higher toxicity toward 4T1 cells than the non-targeted control, while showing lower harm to normal human endothelial cells (HUVECs) compared with free, untargeted TPEN. The resulting tumor-selective profile suggests a widened therapeutic window.

Together, these findings provide proof-of-concept for a precision nanomedicine route to cuproptosis activation using endogenous copper. By pairing robust nanoparticle stability with ligand-directed delivery and metal-chelation chemistry, the authors outline a framework for reducing systemic side effects in copper-based cancer interventions.

“Our approach leverages the high copper levels already present in tumors… [delivering] a chelator that turns the cancer cell’s own biology against itself,” said corresponding author Dr. Ying Chen, emphasizing the cellular-level validation and the potential for future development.

Subject of Research: Cells
Article Title: Preparation and evaluation of iRGD-modified PLGA-PEG nanoparticles encapsulating TPEN
News Publication Date: 14-May-2026
Web References: https://dx.doi.org/10.1016/j.bioana.2026.04.001
References: 10.1016/j.bioana.2026.04.001
Image Credits: Lei Wu, Jianhang Li & Ying Chen
Keywords: cuproptosis, copper-dependent cell death, PLGA-PEG nanoparticles, iRGD, TPEN chelator, targeted drug delivery, tumor-selective cytotoxicity

High-grade serous ovarian cancer is recognized as one of the deadliest cancers affecting women globally. Despite advances in treatment regimens, including chemotherapy and targeted therapies, the prognosis for patients remains bleak, largely due to late-stage diagnosis and the cancer’s intrinsic ability to develop resistance to treatment. As scientists strive to uncover the molecular pathways driving this malignancy, the role of non-coding RNAs has gained increasing recognition. These molecular players, often ignored in the past, are now positioned as critical regulators of gene expression and cellular processes.

In their research, Xu and colleagues demonstrate that the lncRNA RP11-199F11.2 is markedly overexpressed in HGSOC tissues compared to normal ovarian tissues. This upregulation was confirmed through a series of experiments utilizing quantitative PCR and RNA sequencing techniques. The correlation between RP11-199F11.2 expression levels and tumor aggressiveness lays the groundwork for further exploration into how this lncRNA might influence cancer biology. The team proposes that this overexpression may serve as a biomarker for disease progression and patient stratification.

The connection between RP11-199F11.2 and cuproptosis is particularly noteworthy. Cuproptosis, a form of direct copper-induced cell death, represents a novel angle in cancer research. Unlike apoptosis or necrosis, which have established pathways and implications in tumor biology, cuproptosis introduces a new dimension to our understanding of how metals impact cellular survival. The findings detail how RP11-199F11.2 interacts with FDX1, a crucial protein in copper metabolism, ensuing a cascade of molecular events that promote tumoral cell proliferation.

Mechanistically, the research elucidates that RP11-199F11.2 acts as a molecular sponge, binding to specific microRNAs that would otherwise inhibit FDX1 expression. By sequestering these microRNAs, RP11-199F11.2 effectively upregulates FDX1 levels, enhancing the availability of copper and promoting cell proliferation through cuproptosis pathways. This intricate coupling of lncRNA and microRNA highlights the complexity of gene regulation within cancer cells, revealing avenues for novel therapeutic strategies that may target these interactions.

Interestingly, the researchers explored the therapeutic potential of depleting RP11-199F11.2 in ovarian cancer cell lines. Results demonstrated a significant reduction in cell proliferation rates upon knockdown of this lncRNA, suggesting that its inhibition could lead to increased sensitivity of cancer cells to existing chemotherapeutics. Moreover, the study proposes the idea of leveraging cuproptosis in a therapeutic context, indicating that manipulating copper levels in tumors could represent a novel approach to cancer treatment.

The implications of these findings extend beyond academic curiosity. With ovarian cancer being notoriously difficult to diagnose and treat effectively, the potential for RP11-199F11.2 as a therapeutic target or prognostic biomarker introduces hope for more individualized treatment protocols in the future. Personalized medicine could become more feasible by incorporating lncRNA profiling into patient management, guiding decisions regarding treatment plans based on the tumor’s specific molecular characteristics.

While the study presents compelling evidence linking RP11-199F11.2 to tumor biology, it also cautions that further research is needed to explore its role in patient-derived samples and to validate these findings across clinical settings. As with any groundbreaking scientific advancement, the journey from laboratory discovery to clinical application is fraught with challenges, and researchers must tackle various hurdles, including regulatory approvals and biotechnological developments, to bring such discoveries into the clinic.

Moreover, this study emphasizes the need for an interdisciplinary approach within cancer research. Collaboration among molecular biologists, oncologists, and geneticists is crucial for deciphering the complex web of interactions that define cancer biology. Future studies could benefit from integrating bioinformatics tools to mine existing datasets for further insights into lncRNA functions across various cancers, potentially leading to new therapeutic targets.

As cancer research continues to evolve, the contributions of studies like that of Xu et al. pave the way for a deeper understanding of the molecular underpinnings of disease. The spotlight on lncRNAs is expected to intensify as science uncovers more about their involvement in cancer and other diseases. Enhanced understanding of these regulatory RNA molecules may not only inform diagnosis but could also lead to innovative therapeutic strategies designed to outsmart cancer at the molecular level.

In summary, the findings of this study are poised to make a significant impact on the field of cancer research. The intricate relationship between lncRNA RP11-199F11.2, copper metabolism, and cell proliferation underscores a complex yet fascinating landscape of gene regulation in high-grade serous ovarian cancer. As researchers build on these discoveries, the future prospects for therapeutic intervention may shift dramatically, offering new hope to patients battling this formidable disease.

The research underscores a sophisticated understanding of cancer biology while also illustrating the potential for novel therapeutic interventions centered around RNA molecules and metal-mediated pathways. As we continue to unravel the mysteries of cancer, each discovery opens new doors and raises further questions, setting the stage for the next generation of targeted therapies.

Subject of Research: Long non-coding RNA RP11-199F11.2, cuproptosis, high-grade serous ovarian cancer

Article Title: lncRNA RP11-199F11.2 promotes high-grade serous ovarian cancer cell proliferation by regulating cuproptosis through FDX1.

Article References:

Xu, S., Wang, L., Wu, Y. et al. lncRNA RP11-199F11.2 promotes high-grade serous ovarian cancer cell proliferation by regulating cuproptosis through FDX1.
Sci Rep (2025). https://doi.org/10.1038/s41598-025-29080-5

Image Credits: AI Generated

DOI: 10.1038/s41598-025-29080-5

Keywords: high-grade serous ovarian cancer, lncRNA, RP11-199F11.2, cuproptosis, FDX1, cancer proliferation, therapeutic targets, biomarker, molecular biology.